Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis

Detalles Bibliográficos
Autores principales: Gillmore, Julian D, Falk, Rodney H, Maurer, Mathew S, Hanna, Mazen, Karsten, Verena, Vest, John, Gollob, Jared, Hawkins, Philip N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Oral Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641992/
http://dx.doi.org/10.1186/1750-1172-10-S1-O21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641992/
http://dx.doi.org/10.1186/1750-1172-10-S1-O21

Ejemplares similares